GSK
-
GSK pays US$110M upfront for HUTCHMED’s KRAS cancer therapy
The deal also includes up to US$1.185 billion in development, regulatory and commercial milestone payments, bringing its potential total value to US$1.295 billion.
-
GSK gains first global approval for Bepirovirsen as Japan clears new hepatitis B functional cure
The antisense oligonucleotide (ASO) medicine, which GSK will market in Japan as Hibsago, is approved for adults with hepatitis B who meet specified viral markers.
-
GSK secures first lung cancer approval days after US$10.6B Nuvalent acquisition
The US Food and Drug Administration (FDA) approved Jideytro for adults with locally advanced or metastatic ROS1-positive NSCLC who have previously received treatment with a ROS1 kinase inhibitor.
-
GSK launches Shingrix in South Africa following SAHPRA registration
The vaccine was registered earlier this month by the South African Health Products Regulatory Authority (SAHPRA), paving the way for large-scale importation and commercial distribution.
-
GSK-Spero Therapeutics’ Utebzi earns FDA approval to combat rising global antimicrobial resistance
More than 3 million cases of complicated UTIs are recorded annually in the United States, and treatment failure affects up to one-third of patients.
-
GSK strikes US$10.6B Nuvalent deal to strengthen lung cancer pipeline
The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.
-
GSK expands China footprint through Sino Biopharmaceutical partnership for Hepatitis B therapy bepirovirsen
CTTQ will also purchase a supply of bepirovirsen for an initial period of five and a half years, while GSK will record product sales from the arrangement, though the companies are not disclosing the financial value of the deal.
-
GSK bets US$1B on SiranBio’s ALK7 siRNA to disrupt the obesity market
The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.
-
GSK’s Efimosfermin receives dual fast-track designations for MASH treatment
The US Food and Drug Administration granted the therapy Breakthrough Therapy Designation, while the European Medicines Agency awarded it Priority Medicines status.
-
GSK’s Exdensur secures NMPA approval in China for chronic rhinosinusitis
The medication works as an add-on therapy alongside intranasal corticosteroids for patients whose condition fails to respond adequately to systemic corticosteroids or surgical intervention.